Literature DB >> 12535573

In vitro and in vivo models for assessing drug efflux transporter activity.

Yan Zhang1, Corbin Bachmeier, Donald W Miller.   

Abstract

Determining the activity of drug efflux transport proteins has important implications in the identification of substrates and/or inhibitors of the various transport systems, as well as mechanistic determination of localization, and functional role of the transporters in absorption, distribution and elimination of compounds in the body. This review examines both in vitro and in vivo approaches used to determine drug efflux transporter activity, their applications, and advantages and potential limitations.

Mesh:

Substances:

Year:  2003        PMID: 12535573     DOI: 10.1016/s0169-409x(02)00170-9

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  14 in total

Review 1.  Opioid analgesics and P-glycoprotein efflux transporters: a potential systems-level contribution to analgesic tolerance.

Authors:  Susan L Mercer; Andrew Coop
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

2.  Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis.

Authors:  Timothy J Spitzenberger; David Heilman; Casey Diekmann; Elena V Batrakova; Alexander V Kabanov; Howard E Gendelman; William F Elmquist; Yuri Persidsky
Journal:  J Cereb Blood Flow Metab       Date:  2006-10-25       Impact factor: 6.200

3.  Different structures of berberine and five other protoberberine alkaloids that affect P-glycoprotein-mediated efflux capacity.

Authors:  Yi-Ting Zhang; Yu-Qi Yu; Xiao-Xia Yan; Wen-Jie Wang; Xiao-Ting Tian; Le Wang; Wei-Liang Zhu; Li-Kun Gong; Guo-Yu Pan
Journal:  Acta Pharmacol Sin       Date:  2018-11-15       Impact factor: 6.150

4.  Assessment of P-glycoprotein activity in the Blood-Brain Barrier (BBB) using Near Infrared Fluorescence (NIRF) imaging techniques.

Authors:  Ngoc H On; Fang Chen; Martha Hinton; Donald W Miller
Journal:  Pharm Res       Date:  2011-05-20       Impact factor: 4.200

5.  The P-glycoprotein inhibitor GF120918 modulates Ca2+-dependent processes and lipid metabolism in Toxoplasma gondii.

Authors:  Iveta Bottova; Ursula Sauder; Vesna Olivieri; Adrian B Hehl; Sabrina Sonda
Journal:  PLoS One       Date:  2010-04-08       Impact factor: 3.240

Review 6.  Liver and Kidney on Chips: Microphysiological Models to Understand Transporter Function.

Authors:  S Y Chang; E J Weber; Kp Van Ness; D L Eaton; E J Kelly
Journal:  Clin Pharmacol Ther       Date:  2016-08-27       Impact factor: 6.875

7.  D-glucose triggers multidrug resistance-associated protein (MRP)-mediated secretion of fluorescein across rat jejunum in vitro.

Authors:  Igor Legen; Albin Kristl
Journal:  Pharm Res       Date:  2004-04       Impact factor: 4.200

8.  Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo.

Authors:  Andrew Collett; Jolanta Tanianis-Hughes; David Hallifax; Geoff Warhurst
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.200

Review 9.  Exploring the cellular accumulation of metal complexes.

Authors:  Cindy A Puckett; Russell J Ernst; Jacqueline K Barton
Journal:  Dalton Trans       Date:  2009-12-23       Impact factor: 4.390

10.  P-glycoprotein at the blood-brain barrier: kinetic modeling of 11C-desmethylloperamide in mice using a 18F-FDG μPET scan to determine the input function.

Authors:  Lieselotte Moerman; Dieter De Naeyer; Paul Boon; Filip De Vos
Journal:  EJNMMI Res       Date:  2011-07-29       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.